ArticleOncogene2019

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.

Kimio Yonesaka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.